食管胃结合部腺癌行联合脏器切除指征及疗效评价  

The indication and efficacy evaluation of combined multiple organ resections in treating patients with adenocarcinoma of the esophagogastric junction

作　　者：师英强[1] 

机构地区：[1]复旦大学附属肿瘤医院胃及软组织外科,上海200032

出　　处：《中国实用外科杂志》2012年第4期298-300,共3页Chinese Journal of Practical Surgery

摘　　要：食管胃结合部腺癌(AEG)无论从发病机制还是生物学行为上,均不同于食管癌和胃癌,外科治疗时常需考虑是否行联合脏器切除术,尤其是脾脏切除。然而,行脾脏切除术对此类病人术后存活率的影响目前尚存在一定争议。因此,临床上行手术AEG治疗时,应首先明确肿瘤的不同分型、慎重考虑手术的难易程度、全面综合评估原发灶与脾脏的关系及脾门淋巴结的状态,再决定是否行联合脾脏等脏器切除术。Adenocarcinoma of the esophagogastric junction （AEG）, in terms of pathogenesis or biological characteristic, is different from esophageal cancer and gastric cancer. Whether need to perform combined multiple organ resections, especially splenectomy, should be considered when treating patients with AEG by surgery. However, there are some controversies about the postoperative survival rate of such patients performed splenectomy. Therefore, when treating such patients by surgery, different types of tumors should be ascertained and difficulty level of surgery should be considered. Furthermore, the relation of primary cancer and spleen as well as status of splenic hilus lymph node should be evaluated comprehensively. Thereafter, it is proper to decide whether combined splenectomy should be performed.

关 键 词：食管胃结合部癌 脾脏切除 

分 类 号：R6[医药卫生—外科学]